	• •	\mathcal{M}
		PTO/SB/21 (04-07)
	U.S.	Approved for use through 09/30/2007. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no	persons are required to respond to a co	ollection of information unless it displays a valid OMB control number.
E 1400	Application Number	10/580,485
TRANSMITTAL	Filing Date	May 24, 2006
30 2001 E FORM	First Named Inventor	Joachim Moormann
. · · · · · · · · · · · · · · · · · · ·	Art Unit	1614
	Examiner Name	
a (to possed for all correspondence after initial filing	Attorney Docket Number	
Total Number of Pages in This Submission	Altoniey bocket Number	RO4246US (#90568)
	ENCLOSURES (Check al	ll that apply)
		After Allowance Communication to TC
Fee Transmittal Form	Drawing(s)	
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
	Petition to Convert to a	Proprietary Information
After Final	Provisional Application Power of Attorney, Revocation	on
Affidavits/declaration(s)	Change of Correspondence	Address Status Letter
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):
<u> </u>	Request for Refund	return postcard receipt and copies of
Express Abandonment Request		prior art documents
X Information Disclosure Statement	CD, Number of CD(s)	
	Landscape Table on C	D
	Remarks	
Document(s)		
Reply to Missing Parts/ Incomplete Application		
Reply to Missing Parts		
under 37 CFR 1.52 or 1.53		
SIGNATU	IRE OF APPLICANT, ATTO	DRNEY, OR AGENT
m Name D. Peter Hochberg Co.,	L.P.A.	
ignature		
6/48/4VL7		
rinted name D. Peter Hochberg		
	-07 T	Reg. No. 24 602
ate July 27, 21	シレ /	24,603
CER	TIFICATE OF TRANSMISS	SION/MAILING
hereby certify that this correspondence is being	g facsimile transmitted to the USP1	TO or deposited with the United States Postal Service with
ufficient postage as first class mail in an envelope date shown below:	ppe addressed to: Commissioner fo	or Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
ignature	1/0	And the state of t
n 1- W4		
yped or printed name Sean F. Mellino	<u> </u>	Date 07/27/2007
ped or printed name Sean F. Mellino		, 0//2//2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service as First Class mail in an anywelope addressed: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date

cooled below:

7(27/07

Sean Mellino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Joachim Moormann, et al.

Serial No.

10/580,485 (Conf. No. 2532)

Filing Date

May 24, 2006

Examiner

Group Art Unit:

1614

Title

ORAL FORMULATIONS OF DEOXYPEGANINE AND

THEIR USES

Attorney File:

RO4246US (#90568)

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97

Mail Stop Amendment Commissioner for Patents P O Box 1450 Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to call the Examiner's attention to the references listed on the attached Form PTO-1449. Copies of the non-patent references are enclosed made of record in earlier Information Disclosure Statements are enclosed.

In accordance with 37 C.R.F. 1.97(b)(3), and as this Information Disclosure Statement is being filed before the issuance of an Office action on the merits of the application, no additional statement and/or fee is required.

In accordance with 37 C.F.R. 1.97(g) and 37C.F.R.1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.

Date:_

D. Peter Hochberg Co., L.P.A. 1940 E.6th Street – 6th Floor

Cleveland, OH 44114

(216) 771-3800

DPH/SM

Respectfully submitted,

D. Peter Hochberg

Reg. No. 24,603

FORM PTO-1449

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant

Joachim Moormann, et al.

Serial No.

10/580,485 (Conf. No. 2532)

Filing Date

May 24, 2006

Examiner

Group Art Unit:

1614

Title

ORAL FORMULATIONS OF DEOXYPEGANINE AND

THEIR USES

Attorney File:

RO4246US (#90568)

Mail Stop Amendment Commissioner for Patents P O Box 1450

Alexandria, Virginia, 22313-1450

U S PATENT DOCUMENTS

Examiner

Document

Initial

Number

Date

Name

U.S. Published Applications

Examiner

Document

Initial

Number

Date

Name

Foreign Patent Documents

Examiner

Document

Country

Translation

Initial

Number

Date

(Yes/No)

Other Prior Art (Inc. Author, Title, Date, Pertinent Pages, Etc)

Examiner			
<u>Initial</u>	Document Sargazakov, et al.; Khim. Prir. Soedin. 4 (1990), 506-507 Morris, et al.; J. Amer. Chem. Soc. 57 (1935) "Deoxypeganine Injection Solution;" Sadikova, et al.; HCaplus; Vol. 121, No. 8 (August 22, 1994), Abstract		
	"Monoamine Oxidase Inhibitors;" Keung, W.M.; Expert Opinion on Therapeutic Patents; Vol. 12, No. 12 (December 1, 2002); pages 1813-1829		
Examiner	Date Considered:		
Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant		